Croft S M, Schiffman G, Snyder E, Herrmann K, James K, Jarrett M P
J Rheumatol. 1984 Apr;11(2):141-6.
Several in vitro studies have demonstrated a polyclonal B cell response to antigenic stimulation in patients with systemic lupus erythematosus (SLE). To determine if this polyclonal response occurs in vivo, 18 patients with SLE were antigenically stimulated with the pneumococcal vaccine Pneumovax . Mean antibody response to immunization was the same in SLE and normal control subjects. Although elevated antibody levels to several viruses were present in SLE subjects preimmunization, these levels did not change postimmunization. Total immunoglobulin levels, immune complex levels, and antiblood group B antibody levels did not change in SLE patients after immunization. Antiblood group A titers rose in both SLE patients and normals due to a media contaminant in the Pneumovax . Thus, SLE patients appear to have a specific antibody response to antigenic stimulation with pneumococcal polysaccharide. Polyclonal activation as seen in vitro in SLE may be more restricted in vivo.
多项体外研究表明,系统性红斑狼疮(SLE)患者存在针对抗原刺激的多克隆B细胞反应。为确定这种多克隆反应是否在体内发生,对18例SLE患者用肺炎球菌疫苗“沛儿”进行抗原刺激。SLE患者和正常对照受试者对免疫接种的平均抗体反应相同。尽管SLE受试者在免疫接种前存在针对多种病毒的抗体水平升高,但这些水平在免疫接种后并未改变。SLE患者免疫接种后总免疫球蛋白水平、免疫复合物水平和抗B血型抗体水平均未改变。由于“沛儿”中的培养基污染物,SLE患者和正常人的抗A血型滴度均升高。因此,SLE患者似乎对肺炎球菌多糖抗原刺激有特异性抗体反应。SLE患者体外所见的多克隆激活在体内可能受到更多限制。